Optimum Nutrition brings velvety smooth flavor to market with latest launch
DOWNERS GROVE, Ill. – Optimum Nutrition on Tuesday announced the arrival of the newest flavor addition to its Platinum HydroWhey line – red velvet cake. The product offers ON's hydrolyzed whey protein formula in a delicious, on-trend flavor for athletes seeking the most advanced fast-acting whey protein for muscle building and recovery.
"Red velvet cake is an in-demand flavor – but it wasn't enough for ON just to jump on the bandwagon," stated Stuart Heflin, director of North America marketing for ON. "Our iteration had to meet our high ON standard for innovation and the result is a formulation that captures the taste of red velvet cake perfectly – including the hint of cream cheese frosting."
The new Platinum HydroWhey delivers fast-digesting whey protein that provides essential nutrients to help support muscle recovery after an intense workout. Each serving contains 30 grams of protein, 15.5 grams of naturally occurring essential amino acids and nearly nine grams of naturally occurring and added BCAA's, including leucine, isoleucine and valine. The powder is instantized to mix easily with a spoon and can be combined with water, milk or milk alternatives like soy or almond milk.
"By hydrolyzing whey protein isolates to break larger proteins down into smaller pieces, these ultra-pure whey isolates in our Platinum HydroWhey get into your system rapidly, helping the muscles to start recovering from heavy training," Heflin said.
Sanofi Pasteur to start shipping new flu vaccines
SWIFTWATER, Pa. – Sanofi Pasteur on Tuesday announced today that its first doses of Fluzone for the 2016-2017 influenza season have been released by the U.S. Food and Drug Administration for shipment.
In the 2015-2016 influenza season, 50% of seniors who were vaccinated received Fluzone High-Dose vaccine, and this number is expected to rise to 60% in the coming season.
“There is general awareness of influenza among the public given its widespread prevalence,” stated David Greenberg, associate VP and regional medical head North America, Sanofi Pasteur. “What is not well known is that influenza can be life-threatening and have a lasting health impact, especially for the most vulnerable populations.”
This shipment represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year.
To address recommendations by the Advisory Committee on Immunization Practices, Sanofi Pasteur has increased production of Fluzone Quadrivalent vaccine where possible. Sanofi Pasteur is the sole provider of injectable influenza vaccine for pediatric patients six months through 35 months of age.
Influenza activity peaked noticeably late last season occurring in early March 2016. Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
NBTY’s Ester C clinically proven to stay in the body longer
RONKONKOMA, N.Y. – A new clinical study conducted by NBTY demonstrated that Ester-C, a patented form of Vitamin C, stays in immune cells longer than regular Vitamin C (ascorbic acid) currently on the market, NBTY announced Monday.
The study, published in SpringerPlus, reports that Ester-C significantly increases vitamin C concentrations in white blood cells (leukocytes; cell of the immune system) up to 24 hours following a single oral administration of 1,000 mg vitamin C.
"This study is a great example of the commitment NBTY has to scientific diligence around our product innovations," stated Susan Hazels Mitmesser, senior director Nutrition and scientific affairs NBTY and lead author of the study. "As new ingredients and areas of research emerge, our scientific leadership will continue to be a priority and a differentiator in the scientific community and the supplement market with NBTY products leading the way."
"Ester-C is the only product of its kind on the market, and customers can easily find it by the '24-Hour Immune Support' call out on the label," added John Frame, VP marketing for Ester-C. "This product has been clinically studied to stay in the white blood cells longer than regular Vitamin-C – a distinct advantage to anyone looking to nutritionally support their immune system all day long."
This is the first clinical trial comparing vitamin C retention in leukocytes between Ester-C and ascorbic acid in both male and female nonsmokers.
In this double-blind, placebo-controlled, crossover trial, thirty healthy subjects aged 18–60 years were randomized to receive placebo (0 mg vitamin C), ascorbic acid (1,000 mg vitamin C), and Ester-C (1,000 mg vitamin C), each preceded by a 7-day washout period. The Ester-C group had a significantly higher mean concentration change in leukocyte vitamin C, while there was no change in the ascorbic acid or placebo groups. The Ester-C group also had a significantly higher percent change in leukocyte vitamin C compared to ascorbic acid at 8- and 24-hrs after the oral consumption.